Mucin 1 - Pipeline Review, H2 2018 - ResearchAndMarkets.com
The "Mucin 1 - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.This report outlays comprehensive information on the Mucin 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Mucin 1 targeted therapeutics development with respective active and dormant or discontinued projects.
- The report provides a snapshot of the global therapeutic landscape for Mucin 1
- The report reviews Mucin 1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Mucin 1 targeted therapeutics and enlists all their major and minor projects
- The report assesses Mucin 1 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Mucin 1 targeted
- Akshaya Bio Inc.
- Bavarian Nordic A/S
- Bioleaders Corp.
- Boehringer Ingelheim GmbH
- Etubics Corp.
- GeoVax Labs Inc.
- Merck KGaA
- Minerva Biotechnologies Corp.
- NantKwest Inc.
- Peptron Inc.
- Transgene SA
- Vaxil Bio Therapeutics Ltd.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wncxng/mucin_1?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20181018005431/en/